


Fiocruz RNA Platform

Seeding the innovation ecosystem in Latin America

Context- Apartheid of Vaccines

COVID-19 GLOBAL VACCINE TRACKER



In 2021, at the height of the COVID-19 pandemic, less developed countries still faced difficulties in obtaining vaccines against the disease

SOURCES: OFFICIAL DATA; OUR WORLD IN DATA


DATA THROUGH 9/21/2021

FORTUNE

Context

Apartheid of Vaccines

Given this situation, the World Health Organization (WHO) invited companies and institutes interested in producing an mRNA-based vaccine and making these vaccines available to low-income populations.



Context - RNA

Brazilian Conquest

The Oswaldo Cruz Foundation has been selected by the World Health Organization (WHO) as a Center for the Development and Production of mRNA Vaccines in Latin America.




CORONAVÍRUS

Fiocruz é escolhida pela OMS como centro de desenvolvimento e produção de vacinas de RNA mensageiro na América Latina

Outra proposta da Argentina também foi selecionada. Fundação terá à disposição uma equipe de especialistas de todo o mundo para contribuir com diferentes experiências durante o desenvolvimento do novo imunizante.

Por G1


21/09/2021 19h10 · Atualizado há 4 anos



Brazilian RNA


Structure

saRNA construction



✓ Two different antigens
allowing broadly protection

mRNA construction




✓ Altered Spike
construction with diverse
regulatory elements

Brazilian RNA Vaccine


Formulations

More than 20 of ionizable lipids x combinations of structures have been fully developed at Bio-Manguinhos.



Brazilian RNA Vaccine

Patent Application




Brazilian RNA Vaccine

Manufacturing



The first RNA GMP area in Latin America



Brazilian RNA Platform

Dominating the product life cycle




Early Development

- Antigen design
- RNAm backbone
- Formulation development



Proof of Principle

- Pilot scale production
- Non-clinical lots
- Animal tests



Scaling up

- Scaling up studies
- Process improvements




GMP production

- Clinical batches production

Today, we are able to provide services covering the entire foundation of mRNA vaccine development.

Brazilian RNA Platform



Brazilian RNA Platform

COVID Vaccine

RSV Vaccine

Yellow Fever

Tuberculosis

Monoclonal Antibodies

Advanced Therapies

Bio-Manguinhos/Fiocruz

Hub for Latin American RNA Innovation Ecosystem

Our goal is to foster the development of an RNA innovation ecosystem in Latin America, catalyzing research and development as well as manufacturing capabilities, and advocating for equitable access to these cutting-edge products across the region.





Thank You!

business.development@bio.fiocruz.br



MINISTÉRIO DA
SAÚDE

